Marker Therapeutics’ (MRKR) “Strong-Buy” Rating Reiterated at WBB Securities

WBB Securities reiterated their strong-buy rating on shares of Marker Therapeutics (NASDAQ:MRKR) in a research report report published on Tuesday morning, Marketbeat Ratings reports. WBB Securities currently has a $12.50 price target on the stock.

MRKR has been the subject of a number of other research reports. Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th. Canaccord Genuity Group assumed coverage on Marker Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $8.00 price objective for the company.

Marker Therapeutics Stock Performance

Shares of MRKR stock opened at $1.10 on Tuesday. The stock’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $2.69. Marker Therapeutics has a twelve month low of $1.10 and a twelve month high of $5.99. The company has a market capitalization of $11.78 million, a price-to-earnings ratio of -0.92 and a beta of 1.54.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The firm had revenue of $1.22 million during the quarter, compared to the consensus estimate of $5.25 million. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. On average, analysts forecast that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Trading of Marker Therapeutics

A number of hedge funds have recently bought and sold shares of MRKR. Millennium Management LLC acquired a new position in shares of Marker Therapeutics during the fourth quarter valued at about $50,000. Invst LLC acquired a new position in Marker Therapeutics in the 3rd quarter valued at approximately $56,000. Northern Trust Corp raised its holdings in Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after acquiring an additional 21,703 shares in the last quarter. LPL Financial LLC bought a new stake in shares of Marker Therapeutics in the 4th quarter worth approximately $248,000. Finally, Aisling Capital Management LP grew its holdings in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after purchasing an additional 11,084 shares in the last quarter. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.